Nektar Therapeutics Shares Outstanding 2006-2020 | NKTR

Nektar Therapeutics shares outstanding from 2006 to 2020. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Nektar Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 179
2019 175
2018 180
2017 156
2016 140
2015 132
2014 127
2013 116
2012 115
2011 113
2010 94
2009 93
2008 92
2007 92
2006 90
2005 86
Nektar Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2020-12-31 179
2020-09-30 179
2020-06-30 178
2020-03-31 177
2019-12-31 175
2019-09-30 175
2019-06-30 175
2019-03-31 174
2018-12-31 180
2018-09-30 173
2018-06-30 182
2018-03-31 161
2017-12-31 156
2017-09-30 163
2017-06-30 155
2017-03-31 154
2016-12-31 140
2016-09-30 137
2016-06-30 136
2016-03-31 136
2015-12-31 132
2015-09-30 133
2015-06-30 132
2015-03-31 136
2014-12-31 127
2014-09-30 132
2014-06-30 127
2014-03-31 124
2013-12-31 116
2013-09-30 116
2013-06-30 116
2013-03-31 115
2012-12-31 115
2012-09-30 115
2012-06-30 115
2012-03-31 115
2011-12-31 113
2011-09-30 114
2011-06-30 114
2011-03-31 109
2010-12-31 94
2010-09-30 94
2010-06-30 94
2010-03-31 94
2009-12-31 93
2009-09-30 93
2009-06-30 93
2009-03-31 93
2008-12-31 92
2008-09-30 92
2008-06-30 92
2008-03-31 92
2007-12-31 92
2007-09-30 92
2007-06-30 92
2007-03-31 91
2006-12-31 90
2006-09-30 90
2006-06-30 90
2006-03-31 89
2005-12-31 86
2005-09-30 86
2005-06-30 85
2005-03-31 85
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $3.464B $0.153B
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $79.622B 43.54
Takeda Pharmaceutical (TAK) Japan $53.899B 9.87
Astellas Pharma (ALPMY) Japan $28.188B 17.40
Eisai (ESALY) Japan $19.828B 21.99
Catalent (CTLT) United States $18.827B 49.82
Grifols, S.A (GRFS) Spain $12.362B 14.38
Jazz Pharmaceuticals (JAZZ) Ireland $9.513B 15.89
Neurocrine Biosciences (NBIX) United States $9.130B 21.04
United Therapeutics (UTHR) United States $9.075B 17.62
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $7.997B 0.00
IPSEN SA ADR (IPSEY) France $7.765B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $7.022B 0.00
Evotec AG (EVTCY) Germany $6.594B 445.28
Orion OYJ (ORINY) Finland $5.789B 0.00
Ionis Pharmaceuticals (IONS) United States $5.744B 0.00
Sage Therapeutics (SAGE) United States $4.358B 0.00
Hypermarcas (HYPMY) Brazil $3.972B 15.68
Turning Point Therapeutics (TPTX) United States $3.577B 0.00
PTC Therapeutics (PTCT) United States $3.417B 0.00
ChemoCentryx (CCXI) United States $3.246B 0.00
Cronos Group (CRON) Canada $3.012B 0.00
Revolution Medicines (RVMD) United States $2.959B 0.00
Tilray (TLRY) Canada $2.954B 0.00
Relay Therapeutics (RLAY) United States $2.947B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.894B 17.92
Pacira BioSciences (PCRX) United States $2.766B 46.72
Organogenesis Holdings (ORGO) United States $2.747B 165.08
Corcept Therapeutics (CORT) United States $2.671B 26.78
Xencor (XNCR) United States $2.449B 0.00
USANA Health Sciences (USNA) United States $2.039B 16.88
BioCryst Pharmaceuticals (BCRX) United States $1.997B 0.00
FibroGen (FGEN) United States $1.833B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.766B 11.33
Ironwood Pharmaceuticals (IRWD) United States $1.708B 13.43
Heron Therapeutics (HRTX) United States $1.633B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.574B 0.00
ImmunoGen (IMGN) United States $1.502B 0.00
Endo (ENDP) Ireland $1.443B 2.18
AlloVir (ALVR) United States $1.438B 0.00
Translate Bio (TBIO) United States $1.417B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.416B 0.00
Sundial Growers (SNDL) Canada $1.406B 0.00
Aclaris Therapeutics (ACRS) United States $1.382B 0.00
Indivior (INVVY) United States $1.363B 0.00
Ocular Therapeutix (OCUL) United States $1.209B 0.00
Zogenix (ZGNX) United States $1.060B 0.00
Trillium Therapeutics (TRIL) Canada $1.028B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.022B 0.00
CLINIGEN GP (CLIGF) United Kingdom $0.942B 0.00
Radius Health (RDUS) United States $0.924B 0.00
4D Molecular Therapeutics (FDMT) $0.886B 0.00
Vectura Group (VEGPF) United Kingdom $0.864B 0.00
Ardelyx (ARDX) United States $0.858B 0.00
Bioventus (BVS) United States $0.842B 0.00
Collegium Pharmaceutical (COLL) United States $0.819B 30.62
Aerie Pharmaceuticals (AERI) United States $0.809B 0.00
Esperion Therapeutics (ESPR) United States $0.761B 0.00
Karyopharm Therapeutics (KPTI) United States $0.729B 0.00
Silence Therapeutics (SLN) United Kingdom $0.689B 0.00
Chinook Therapeutics (KDNY) United States $0.674B 0.00
Calliditas Therapeutics AB (CALT) Sweden $0.671B 0.00
Rafael Holdings (RFL) United States $0.657B 0.00
Harpoon Therapeutics (HARP) United States $0.648B 0.00
VAXART, INC (VXRT) United States $0.630B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.609B 0.00
KalVista Pharmaceuticals (KALV) United States $0.594B 0.00
Nanobiotix S.A (NBTX) France $0.570B 0.00
Siga Technologies (SIGA) United States $0.557B 9.31
Crinetics Pharmaceuticals (CRNX) United States $0.553B 0.00
Sigilon Therapeutics (SGTX) $0.537B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.517B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.504B 0.00
Flexion Therapeutics (FLXN) United States $0.470B 0.00
TherapeuticsMD (TXMD) United States $0.466B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.461B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.461B 10.83
Altimmune (ALT) United States $0.456B 0.00
Molecular Templates (MTEM) United States $0.455B 0.00
Akebia Therapeutics (AKBA) United States $0.454B 0.00
AVITA Medical (RCEL) United States $0.447B 0.00
Summit Therapeutics (SMMT) United States $0.444B 0.00
Foghorn Therapeutics (FHTX) United States $0.423B 0.00
Jounce Therapeutics (JNCE) United States $0.413B 0.00
PROFOUND MEDICL (PROF) Canada $0.409B 0.00
Nature's Sunshine Products (NATR) United States $0.400B 19.08
DURECT (DRRX) United States $0.389B 0.00
MEI Pharma (MEIP) United States $0.380B 0.00
Acutus Medical (AFIB) United States $0.362B 0.00
Innate Pharma SA (IPHYF) France $0.352B 0.00
Redhill Biopharma (RDHL) Israel $0.329B 0.00
Oncternal Therapeutics (ONCT) United States $0.320B 0.00
Clever Leaves Holdings (CLVR) United States $0.276B 0.00
VYNE Therapeutics (VYNE) United States $0.274B 0.00
Infinity Pharmaceuticals (INFI) United States $0.264B 0.00
Alpine Immune Sciences (ALPN) United States $0.263B 0.00
Taiwan Liposome (TLC) Taiwan $0.252B 0.00
Inotiv (NOTV) United States $0.250B 0.00
CASI Pharmaceuticals (CASI) United States $0.250B 0.00
KemPharm (KMPH) United States $0.244B 0.00
Xeris Pharmaceuticals (XERS) United States $0.234B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.231B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.215B 0.00
4D Pharma (LBPS) United Kingdom $0.213B 0.00
Sierra Oncology (SRRA) Canada $0.209B 0.00
Progenity (PROG) United States $0.203B 0.00
Lannett Co Inc (LCI) United States $0.197B 6.61
Iterum Therapeutics (ITRM) Ireland $0.194B 0.00
CTI BioPharma (CTIC) United States $0.189B 0.00
IMV INC (IMV) Canada $0.187B 0.00
OptiNose (OPTN) United States $0.186B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.179B 0.00
Jaguar Animal Health (JAGX) United States $0.169B 0.00
Novan (NOVN) United States $0.167B 0.00
Heat Biologics (HTBX) United States $0.164B 0.00
Gain Therapeutics (GANX) United States $0.164B 0.00
Adherex Technologies (FENC) United States $0.163B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.163B 0.00
SCYNEXIS (SCYX) United States $0.159B 0.00
Calithera Biosciences (CALA) United States $0.158B 0.00
Vivos Therapeutics (VVOS) $0.152B 0.00
Qilian Holding Group (QLI) China $0.149B 0.00
Champions Oncology (CSBR) United States $0.148B 0.00
Aquestive Therapeutics (AQST) United States $0.147B 0.00
Onconova Therapeutics (ONTX) United States $0.143B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.143B 0.00
Concert Pharmaceuticals (CNCE) United States $0.142B 0.00
Ayala Pharmaceuticals (AYLA) Israel $0.138B 0.00
MediWound (MDWD) Israel $0.137B 0.00
GlycoMimetics (GLYC) United States $0.135B 0.00
Nutriband (NTRB) United States $0.133B 0.00
Aziyo Biologics (AZYO) United States $0.132B 0.00
Lipocine (LPCN) United States $0.129B 0.00
Genocea Biosciences (GNCA) United States $0.118B 0.00
Natural Alternatives (NAII) United States $0.116B 31.38
La Jolla Pharmaceutical (LJPC) United States $0.112B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.109B 0.00
Minerva Neurosciences (NERV) United States $0.109B 42.33
Otonomy (OTIC) United States $0.107B 0.00
PolarityTE (PTE) United States $0.106B 0.00
Savara (SVRA) United States $0.095B 0.00
Regulus Therapeutics (RGLS) United States $0.094B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.090B 0.00
ElectroCore (ECOR) United States $0.087B 0.00
Recro Pharma (REPH) United States $0.086B 0.00
Assertio Holdings (ASRT) United States $0.084B 0.00
ProPhase Labs (PRPH) United States $0.081B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.077B 0.00
Trimel Pharmaceuticals (ASPCF) Canada $0.075B 0.00
Baudax Bio (BXRX) United States $0.075B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.071B 0.00
Sigyn Therapeutics (SIGY) United States $0.068B 0.00
Addex Therapeutics (ADXN) Switzerland $0.068B 0.00
RENEURON GP (RNUGF) United Kingdom $0.062B 0.00
Biomerica (BMRA) United States $0.058B 0.00
Brickell Biotech (BBI) United States $0.057B 0.00
IntelGenx Technologies (IGXT) Canada $0.054B 0.00
Inhibikase Therapeutics (IKT) United States $0.053B 0.00
HANCOCK JAFFE (HJLI) United States $0.052B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.051B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.047B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.045B 59.80
Viracta Therapeutics (VIRX) United States $0.041B 0.00
Mannatech (MTEX) United States $0.040B 7.03
RXi Pharmaceuticals (PHIO) United States $0.031B 0.00
Petros Pharmaceuticals (PTPI) United States $0.031B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.031B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.027B 0.00
Midatech Pharma (MTP) United Kingdom $0.024B 0.00
JanOne (JAN) United States $0.021B 0.00
China SXT Pharmaceuticals (SXTC) China $0.020B 0.00
Plus Therapeutics (PSTV) United States $0.019B 0.00
Cyanotech (CYAN) United States $0.019B 15.70
Sonoma Pharmaceuticals (SNOA) United States $0.018B 0.00
SHINECO INC (TYHT) China $0.018B 0.00
Xenetic Biosciences (XBIO) United States $0.017B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00